{"filing":{"accession_number":"0001193125-26-424644","cik":"0001314102","ticker":"EYPT","company_name":"EyePoint, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"eypt-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm"},"events":[{"id":35933,"run_id":33121,"accession_number":"0001193125-26-424644","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"EyePoint announced topline results from the LUCIA Phase 3 clinical trial of DURAVYU for wet AMD. The trial failed to meet its primary endpoint of non-inferiority in BCVA versus aflibercept control, though it met key secondary endpoints including treatment burden reduction and demonstrated visual improvement. This is a material clinical development milestone that would affect investor assessment of the company's pipeline and regulatory prospects, but does not fit neatly into financial, legal, or governance categories—it is a clinical/operational event central to the company's product development strategy.","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40167,"accession_number":"0001193125-26-424644","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EyePoint announced topline results from the LUCIA Phase 3 clinical trial of DURAVYU for wet AMD. The trial failed to meet its primary endpoint of non-inferiority in BCVA versus aflibercept control, though it met key secondary endpoints including treatment burden reduction and demonstrated visual improvement. This is a material clinical development milestone that would affect investor assessment of the company's pipeline and regulatory prospects, but does not fit neatly into financial, legal, or governance categories—it is a clinical/operational event central to the company's product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:06:37.835262+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40167,"accession_number":"0001193125-26-424644","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EyePoint announced topline results from the LUCIA Phase 3 clinical trial of DURAVYU for wet AMD. The trial failed to meet its primary endpoint of non-inferiority in BCVA versus aflibercept control, though it met key secondary endpoints including treatment burden reduction and demonstrated visual improvement. This is a material clinical development milestone that would affect investor assessment of the company's pipeline and regulatory prospects, but does not fit neatly into financial, legal, or governance categories—it is a clinical/operational event central to the company's product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:06:37.835262+00:00","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-10-19"}]}